Mechanism of free fatty acid-induced insulin resistance in humans. 1996

M Roden, and T B Price, and G Perseghin, and K F Petersen, and D L Rothman, and G W Cline, and G I Shulman
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, USA.

To examine the mechanism by which lipids cause insulin resistance in humans, skeletal muscle glycogen and glucose-6-phosphate concentrations were measured every 15 min by simultaneous 13C and 31P nuclear magnetic resonance spectroscopy in nine healthy subjects in the presence of low (0.18 +/- 0.02 mM [mean +/- SEM]; control) or high (1.93 +/- 0.04 mM; lipid infusion) plasma free fatty acid levels under euglycemic (approximately 5.2 mM) hyperinsulinemic (approximately 400 pM) clamp conditions for 6 h. During the initial 3.5 h of the clamp the rate of whole-body glucose uptake was not affected by lipid infusion, but it then decreased continuously to be approximately 46% of control values after 6 h (P < 0.00001). Augmented lipid oxidation was accompanied by a approximately 40% reduction of oxidative glucose metabolism starting during the third hour of lipid infusion (P < 0.05). Rates of muscle glycogen synthesis were similar during the first 3 h of lipid and control infusion, but thereafter decreased to approximately 50% of control values (4.0 +/- 1.0 vs. 9.3 +/- 1.6 mumol/[kg.min], P < 0.05). Reduction of muscle glycogen synthesis by elevated plasma free fatty acids was preceded by a fall of muscle glucose-6-phosphate concentrations starting at approximately 1.5 h (195 +/- 25 vs. control: 237 +/- 26 mM; P < 0.01). Therefore in contrast to the originally postulated mechanism in which free fatty acids were thought to inhibit insulin-stimulated glucose uptake in muscle through initial inhibition of pyruvate dehydrogenase these results demonstrate that free fatty acids induce insulin resistance in humans by initial inhibition of glucose transport/phosphorylation which is then followed by an approximately 50% reduction in both the rate of muscle glycogen synthesis and glucose oxidation.

UI MeSH Term Description Entries
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005230 Fatty Acids, Nonesterified FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form. Fatty Acids, Free,Free Fatty Acid,Free Fatty Acids,NEFA,Acid, Free Fatty,Acids, Free Fatty,Acids, Nonesterified Fatty,Fatty Acid, Free,Nonesterified Fatty Acids
D005260 Female Females
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006003 Glycogen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D018482 Muscle, Skeletal A subtype of striated muscle, attached by TENDONS to the SKELETON. Skeletal muscles are innervated and their movement can be consciously controlled. They are also called voluntary muscles. Anterior Tibial Muscle,Gastrocnemius Muscle,Muscle, Voluntary,Plantaris Muscle,Skeletal Muscle,Soleus Muscle,Muscle, Anterior Tibial,Muscle, Gastrocnemius,Muscle, Plantaris,Muscle, Soleus,Muscles, Skeletal,Muscles, Voluntary,Skeletal Muscles,Tibial Muscle, Anterior,Voluntary Muscle,Voluntary Muscles

Related Publications

M Roden, and T B Price, and G Perseghin, and K F Petersen, and D L Rothman, and G W Cline, and G I Shulman
July 2011, Diabetes care,
M Roden, and T B Price, and G Perseghin, and K F Petersen, and D L Rothman, and G W Cline, and G I Shulman
August 2002, American journal of physiology. Endocrinology and metabolism,
M Roden, and T B Price, and G Perseghin, and K F Petersen, and D L Rothman, and G W Cline, and G I Shulman
March 2002, Diabetes,
M Roden, and T B Price, and G Perseghin, and K F Petersen, and D L Rothman, and G W Cline, and G I Shulman
May 2012, Nihon rinsho. Japanese journal of clinical medicine,
M Roden, and T B Price, and G Perseghin, and K F Petersen, and D L Rothman, and G W Cline, and G I Shulman
July 2021, Endocrine connections,
M Roden, and T B Price, and G Perseghin, and K F Petersen, and D L Rothman, and G W Cline, and G I Shulman
June 2002, Diabetes,
M Roden, and T B Price, and G Perseghin, and K F Petersen, and D L Rothman, and G W Cline, and G I Shulman
September 1998, Diabetes & metabolism,
M Roden, and T B Price, and G Perseghin, and K F Petersen, and D L Rothman, and G W Cline, and G I Shulman
November 2018, Nutrients,
M Roden, and T B Price, and G Perseghin, and K F Petersen, and D L Rothman, and G W Cline, and G I Shulman
October 1997, Endocrinology,
M Roden, and T B Price, and G Perseghin, and K F Petersen, and D L Rothman, and G W Cline, and G I Shulman
March 2007, Endocrine, metabolic & immune disorders drug targets,
Copied contents to your clipboard!